Urokinase type plasminogen activator and the molecular mechanisms of its regulation in cancer

Protein and Peptide Letters

Volumn 24, Issue 10, 2017, Pages 936-946

  Santibanez, Juan F ^a,b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSIDAD BERNARDO O'HIGGINS   (Chile)

Author keywords

Cancer; Epigenetic; MicroRNA; Signaling; Therapies; UPA; UPAR; Urokinase type plasminogen activator; Urokinase type plasminogen activator receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; JANUS KINASE 1; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RELATED PROTEIN 1; MICRORNA; MICRORNA 181; MICRORNA 193A; MICRORNA 23B; MICRORNA 34; MICRORNA 497; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE B; PROTEIN P53; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; UROKINASE RECEPTOR; UVOMORULIN; VERY LATE ACTIVATION ANTIGEN 3; VERY LATE ACTIVATION ANTIGEN 5;

3' UNTRANSLATED REGION; 5' FLANKING REGION; AMINO TERMINAL SEQUENCE; BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; ENDOCYTOSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INTRACELLULAR SIGNALING; MALIGNANT NEOPLASM; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PROSTATE CANCER; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; TRANSCRIPTION REGULATION; GENE EXPRESSION; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION;

CELL PROLIFERATION; GENE EXPRESSION; HUMANS; NEOPLASMS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 85041660436     PISSN: 09298665     EISSN: 18755305     Source Type: Journal    
DOI: 10.2174/0929866524666170818161132     Document Type: Review

References (141)

1. Brooks, S.A.; Lomax-Browne, H.J.; Carter, T.M.; Kinch, C.E.; Hall, D.M. Molecular interactions in cancer cell metastasis. Acta Histochem., 2010, 112, 3-25.
2. Santibanez, J.F. Transforming growth factor-Beta and urokinasetype plasminogen activator: Dangerous partners in tumorigenesisimplications in skin cancer. ISRN Dermatol., 2013, 2013, 597927.
3. Duffy, M.J.; McGowan, P.M.; Gallagher, W.M. Cancer invasion and metastasis: Changing views. J. Pathol., 2008, 214, 283-293.
4. Duffy, M.J. Urokinase-type plasminogen activator: A potent marker of metastatic potential in human cancers. Biochem. Soc. Trans., 2002, 30, 207-210.
5. Blasi, F.; Carmeliet, P. uPAR: A versatile signalling orchestrator. Nat. Rev. Mol. Cell. Biol., 2002, 3, 932-943.
6. Smith, H.W.; Marshall, C.J. Regulation of cell signalling by uPAR. Nat. Rev. Mol. Cell. Biol., 2010, 11, 3-36.
7. Seetoo, D.Q.; Crowe, P.J.; Russell, P.J.; Yang, J.L. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J. Surg. Oncol., 2003, 82, 184-193.
8. Harbeck, N.; Kates, R.E.; Schmitt, M.; Gauger, K.; Kiechle, M.; Janicke, F.; Thomassen, C.; Look, M.P.; Foekens, J.A. Urokinasetype plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin. Breast Cancer, 2004, 5, 348-352.
9. Gunzler, W.A.; Flohe L. Urinary-type Plasminogen Activator (uPA) In: Fibrinolytics and Antifibrinolytics; Professor emeritus F. Bachmann, Ed.; Springer-Verlag. Berlin: Heidelberg. 2001; Vol. 146, pp 91-110.
10. Buko, A.M.; Kentzer, E.J.; Petros, A.; Menon, G.; Zuiderweg, E.R.; Sarin, V.K. Characterization of a posttranslational fucosylation in the growth factor domain of urinary plasminogen activator. Proc. Natl. Acad. Sci., U.S.A., 1991, 88, 3992-3996.
11. Appella, E.; Robinson, E.A.; Ullrich, S.J.; Stoppelli, M.P.; Corti, A.; Cassani, G.; Blasi, F. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J. Biol. Chem., 1987, 262, 4437-4440.
12. Vassalli, J.D.; Baccino, D.; Belin, D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell. Biol., 1985, 100, 86-92.
13. Poliakov, A.; Tkachuk, V.; Ovchinnikova, T.; Potapenko, N.; Bagryantsev, S; Stepanova, V. Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation. Biochem. J., 2001, 355, 639-645.
14. Steffens, G.J, Gunzler, W.A.; Otting, F.; Frankus, E.; Flohe, L. The complete amino acid sequence of low molecular mass urokinase from human urine. Hoppe Seylers Z. Physiol. Chem., 1982, 363, 1043-1058.
15. Ellis, V.; Dano, K. Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation. J. Biol. Chem., 1993, 268, 4806-4813.
16. Rijken, D.C.; Lijnen, H.R. New insights into the molecular mechanisms of the fibrinolytic system. J. Thromb. Haemost. 2009, 7, 4-13.
17. Barinka, C.; Parry, G.; Callahan, J.; Shaw, D.E.; Kuo, A.; Bdeir, K.; Cines, D.B.; Mazar, A.; Lubkowski, J. Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J. Mol. Biol., 2006, 63, 482-495.
18. Thuno, M.; Macho, B.; Eugen-Olsen, J. suPAR: The molecular crystal ball. Dis. Markers, 2009, 27(1) 157-172.
19. Mason, S.D.; Joyce, J.A. Proteolytic networks in cancer. Trends Cell. Biol., 2011, 21, 228-237.
20. Carmeliet, P.; Moons, L.; Lijnen, R.; Baes, M.; Lemaitre, V.; Tipping, P.; Drew, A.; Eeckhout, Y.; Shapiro, S.; Lupu, F.; Collen, D. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat. Genet., 1997, 17, 439-444.
21. He, Y.; Liu, X.D.; Chen, Z.Y.; Zhu, J.; Xiong, Y.; Li, K.; Dong, J.H.; Li, X. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis. Clin. Cancer Res., 2007, 13, 3115-3124.
22. Houck, K.A.; Leung, D.W.; Rowland, A.M.; Winer, J.; Ferrara, N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem., 1992, 267, 26031-26037.
23. Lyons, R.M.; Gentry, L.E.; Purchio, A.F.; Moses, H.L. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J. Cell. Biol., 1990, 110, 1361-1367.
24. Estreicher, A.; Muhlhauser, J.; Carpentier, J.L.; Orci, L.; Vassalli. J.D. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J. Cell. Biol., 1990, 111, 783-792.
25. Dellas, C.; Loskutoff, D.J. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb. Haemost., 2005, 93, 631-640.
26. Hagelgans, A.; Menschikowski, M.;, Fuessel, S.; Nacke, B.; Arneth, B.M.; Wirth, M.P.; Siegert, G. Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: Role of epigenetic mechanisms. Exp. Mol. Pathol., 2013, 94, 458-465.
27. Ye, S.; Goldsmith, E.J. Serpins and other covalent protease inhibitors. Curr. Opin. Struct. Biol., 2001, 11, 740-745.
28. Ulisse, S.; Baldini, E.; Sorrenti, S.; D'Armiento, M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr. Cancer Drug Targets, 2009, 9, 32-71.
29. Lijnen, H.R. Pleiotropic functions of plasminogen activator inhibitor-1. J. Thromb. Haemost., 2005, 3, 35-45.
30. Croucher, D.R.; Saunders, D.N.; Lobov, S.; Ranson, M. Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat. Rev. Cancer, 2008, 8, 535-545.
31. Czekay, R.P.; Kuemmel, T.A.; Orlando, R.A.; Farquhar MG. Direct binding of occupied urokinase receptor (uPAR) to LDL receptorrelated protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol. Biol. Cell, 2001, 12, 1467-1479.
32. Resnati, M.; Guttinger, M.; Valcamonica, S.; Sidenius, N.; Blasi, F.; Fazioli, F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J., 1996, 15, 1572-1582.
33. Nusrat, A.R.; Chapman, H.A. Jr. An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J. Clin. Invest., 1991, 87, 1091-1097.
34. Kugler, M.C.; Wei, Y.; Chapman, H.A. Urokinase receptor and integrin interactions. Curr. Pharma. Des., 2003, 9, 1565-154.
35. Liu, D.; Aguirre-Ghiso, J.A.; Estrada, Y.; Ossowski, L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell, 2002, 1, 445-457.
36. Guerrero, J.; Santibanez, J.F.; Gonzalez, A.; Martinez, J. EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases. Exp. Cell. Res., 2004, 292, 201-208.
37. Aguirre-Ghiso, J.A. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene, 2002, 21, 2513-2524.
38. Zhang, F.; Tom, C.C.; Kugler, M.C.; Ching, T.T.; Kreidberg, J.A.; Wei, Y.; Chapman, H.A. Distinct ligand binding sites in integrin alpha3beta1 regulate matrix adhesion and cell-cell contact. J. Cell. Biol., 2003, 163, 177-188.
39. Juretic, N.; Santibanez J.F.; Hurtado, C.; Martinez, J. ERK 1,2 and p38 pathways are involved in the proliferative stimuli mediated by urokinase in osteoblastic SaOS-2 cell line. J. Cell. Biochem., 2001, 83, 92-98.
40. Kjoller, L.; Hall, A. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J. Cell. Biol., 2001, 152, 1145-1157.
41. Koshelnick, Y.; Ehart, M.; Hufnagl, P.; Heinrich, P.C.; Binder, B.R. Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J. Biol. Chem., 1997; 272, 28563-28567.
42. Eddy, R,J.; Weidmann, M.D.; Sharma, V.P.; Condeelis, J.S. Tumor cell invadopodia: Invasive protrusions that orchestrate metastasis. Trends Cell. Biol., 2017, 27(8), 595-607.
43. Lu, P.; Weaver, V.M.; Werb. Z. The extracellular matrix: A dynamic niche in cancer progression. J. Cell. Biol., 2012, 196, 395-406.
44. Wong, G.S.; Rustgi, A.K. Matricellular proteins: Priming the tumour microenvironment for cancer development and metastasis. Br. J. Cancer, 2013, 108, 755-761.
45. Dano, K.; Behrendt, N.; Hoyer-Hansen, G.; Johnsen, M.; Lund, L.R.; Ploug, M.; Romer, J. Plasminogen activation and cancer. Thromb. Haemost., 2005, 93, 676-681.
46. Baldini, E., Sorrenti, S.; D'Armiento, E.; Di Matteo, F.M.; Catania, A.; Ulisse, S. The urokinase plasminogen activating system in thyroid cancer: Clinical implications. G. Chir., 2012, 33, 305-310.
47. Ossowski, L.; Aguirre-Ghiso, J.A. Urokinase receptor and integrin partnership: Coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell. Biol., 2000, 12, 613-620.
48. Kotipatruni, R.R.; Nalla, A.K.; Asuthkar, S.; Gondi, C.S.; Dinh, D.H.; Rao, J.S. Apoptosis induced by knockdown of uPAR and MMP-9 is mediated by inactivation of EGFR/STAT3 signaling in medulloblastoma. PLoS One, 2012, 7, e44798.
49. Aguirre-Ghiso, J.A.; Liu, D.; Mignatti, A.; Kovalski, K.; Ossowski, L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell., 2001, 12, 863-879.
50. Allgayer, H.; Aguirre-Ghiso, J.A. The urokinase receptor (u-PAR)-A link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS, 2008, 116, 602-614.
51. Noh, H.; Hong, S.; Huang, S. Role of urokinase receptor in tumor progression and development. Theranostics, 2013, 3, 487-495.
52. Tang, L.; Han, X. The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed. Pharmacother., 2013, 67, 179-182.
53. Heissig, B.; Dhahri, D.; Eiamboonsert, S.; Salama, Y.; Shimazu, H.; Munakata, S.; Hattori, K. Role of mesenchymal stem cell-derived fibrinolytic factor in tissue regeneration and cancer progression. Cell. Mol. Life Sci., 2015, 72, 4759-7470.
54. Czekay, R.P.; Kuemmel, T.A. Orlando, R.A.; Farquhar, M.G. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol. Biol. Cell., 2001, 12, 1467-1479.
55. Duffy, M.J.; McGowan, P.M.; Harbeck, N.; Thomssen, C.; Schmitt, M. uPA and PAI-1 as biomarkers in breast cancer: Validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res., 2014, 16, 428.
56. Pavon, M.A.; Arroyo-Solera, I.; Cespedes, M.V.; Casanova, I.; Leon, X.; Mangues, R. uPA/uPAR and SERPINE1 in head and neck cancer: Role in tumor resistance, metastasis, prognosis and therapy. Oncotarget, 2016, 7, 57351-57366.
57. Binder, B.R.; Mihaly, J. The plasminogen activator inhibitor "paradox" in cancer. Immunol. Lett., 2008, 118, 116-124.
58. Montuori, N.; Rossi, G.; Ragno, P. Post-transcriptional regulation of gene expression in the plasminogen activation system. Biol. Chem., 2002, 383, 47-53.
59. Laufs, S.; Schumacher, J.; Allgayer, H. Urokinase-receptor (u-PAR): An essential player in multiple games of cancer: A review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle, 2006, 5, 1760-1771.
60. Helenius, M.A.; Saramaki, O.R.; Linja, M.J.; Tammela, T.L.; Visakorpi. T. Amplification of urokinase gene in prostate cancer. Cancer Res., 2001, 61, 5340-5344.
61. Genes-Genetics Home Reference. ghr.nlm.nih.gov/gene/PLAU#location (Accesed April 15, 2017)
62. Nagamine, Y.; Medcalf, R.L.; Munoz-Canoves, P. Transcriptional and posttranscriptional regulation of the plasminogen activator system. Thromb. Haemost., 2005, 93, 661-675.
63. Crippa, M.P. Urokinase-type plasminogen activator. Int. J. Biochem. Cell. Biol., 2007, 39, 690-694.
64. Villar, V.; Kocic, J.; Bugarski, D.; Jovcic, G.; Santibanez, J.F. SKIP is required for TGF-β1-induced epithelial mesenchymal transition and migration in transformed keratinocytes. FEBS Lett., 2010, 584, 4586-9452.
65. Pakneshan, P.; Tetu, B.; Rabbani, S.A. Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. Clin. Cancer Res., 2004, 10, 3035-3041.
66. Koziczak, M.; Krek, W.; Nagamine, Y. Pocket protein-independent repression of urokinase-type plasminogen activator and plasminogen activator inhibitor 1 gene expression by E2F1. Mol. Cell. Biol., 2000, 20, 2014-2022.
67. Moreau, M.; Mourah, S.; Dosquet, C. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells. Int. J. Cancer, 2011, 128, 1280-1292.
68. Hansen, S.K.; Nerlov, C.; Zabel, U.; Verde, P.; Johnsen, M.; Baeuerle, P.A.; Blasi, F. A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J., 1992, 11, 205-213.
69. Wang, Y., Dang. J,; Wang, H.; Allgayer, H.; Murrell, G.A.; Boyd, D. Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. Eur. J. Biochem., 2000, 267, 3248-3254.
70. Hu, Q.; Lu, Y.Y.; Noh, H.; Hong, S.; Dong, Z.; Ding, H.F.; Su, S.B.; Huang, S. Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression. Oncogene, 2013, 32, 3933-3943
71. Verde, P.; Boast, S.; Franze, A.; Robbiatil F.; Blasi, F. An upstream enhancer and a negative element in the 5' flanking region of the human urokinase plasminogen activator gene. Nucleic Acids Res., 1988, 16, 10699-10716.
72. D'Orazio, D.; Besser, D.; Marksitzer, R.; Kunz, C.; Hume, D.A.; Kiefer, B.; Nagamine, Y. Cooperation of two PEA3/AP1 sites in uPA gene induction by TPA and FGF-2. Gene, 1997, 201, 179-187.
73. Ibanez-Tallon, I.; Caretti, G.; Blasi, F.; Crippa, M.P. In vivo analysis of the state of the human uPA enhancer following stimulation by TPA. Oncogene, 1999, 18, 2836-2845.
74. Hassler, M.R.; Egger, G. Epigenomics of cancer-emerging new concepts. Biochimie, 2012, 94, 2219-2230.
75. Marks, P.A.; Rifkind, R.A.; Richon, V.M.; Breslow, R. Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin. Cancer Res., 2001, 7, 759-760.
76. Pulukuri, S.M.; Estes, N.; Patel. J.; Rao, J.S. Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res., 2007, 67, 930-939.
77. Kandenwein, J.A.; Park-Simon, T.W.; Schramm, J.; Simon, M. uPA/PAI-1 expression and uPA promoter methylation in meningiomas. J. Neurooncol., 2011, 103, 533-539.
78. Sharma, S.; Kelly, T.K.; Jones, P.A. Epigenetics in cancer. Carcinogenesis, 2010, 31, 27-36.
79. Pulukuri, S.M.; Gorantla, B.; Rao. J.S. Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator. J. Biol. Chem., 2007, 282, 35594-35603.
80. Sai, M.; Krishna, P.; Bharathi, G. Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator. J. Biol. Chem., 2007, 282, 35594-35603.
81. Leem, K.H.; Choi, E.Y.; Kim, M.K.; Kim, K.O.; Jang, B.I.; Kimm S,W.; Kim, S.W.; Song, S.K.; Kim, J.R. Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer. Mol. Cell. Biochem., 2010, 343, 163-171.
82. Manasa, V.G.; Kannan, S. Impact of microRNA dynamics on cancer hallmarks: An oral cancer scenario. Tumour Biol., 2017, 39, 1010428317695920.
83. Lin, C.P.; He, L. Noncoding RNAs in cancer development. Ann. Rev. Cancer Biol., 2017, 1, 163-184.
84. Ventura, A.; Jacks, T. MicroRNAs and cancer: Short RNAs go a long way. Cell, 2016, 136, 586-591.
85. Lebrun, J.J. The dual role of tgfβ in human cancer: From tumor suppression to cancer metastasis. ISRN Mol. Biol., 2102, 2012, 381428
86. Nanbu, R.; Menoud, P.A.; Nagamine, Y. Multiple instabilityregulating sites in the 3' untranslated region of the urokinase-type plasminogen activator mRNA. Mol. Cell. Biol., 1994, 14, 4920-4928.
87. Salvi, A.; Sabelli, C.; Moncini, S.; Venturin, M.; Arici, B.; Riva, P.; Portolani, N.; Giulini, S.M.; De Petro, G.; Barlati, S. MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. FEBS J., 2009, 276, 2966-2982.
88. Au Yeung, C.L.; Tsang, T.Y.; Yau, P.L.; Kwok, T.T. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. Oncogene, 2011, 30, 2401-2410.
89. Yan, J.; Jiang, J.Y.; Meng, X.N.; Xiu, Y.L.; Zong, Z.H. MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression. J. Exp. Clin. Cancer Res., 2016, 13, 31.
90. Pang, R.T.; Leung, C.O.; Ye, T.M.; Liu, W.; Chiu, P.C.; Lam, K.K.; Lee, K.F.; Yeung, W.S. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis, 2010, 31, 1037-1044.
91. Noh, H.; Hong, S.; Dong, Z.; Pan, Z.K.; Jing, Q.; Huang, S. Impaired MicroRNA processing facilitates breast cancer cell invasion by upregulating urokinase-type plasminogen activator expression. Genes Cancer, 2011, 2, 140-150.
92. Iliopoulos, D.; Rotem, A.; Struhl, K. Inhibition of miR-193a expression by Max and RXRα activates K-Ras and PLAU to mediate distinct aspects of cellular transformation. Cancer Res., 2011, 71, 5144-5153.
93. Salvi, A.; Condem I.; Abeni, E.; Arici, B.; Grossi, I.; Specchia, C.; Portolani, N.; Barlati, S.; De Petro, G. Effects of miR-193a and sorafenib on hepatocellular carcinoma cells. Mol. Cancer, 2013, 12(1), 162.
94. Li, X.F.; Yan, P.J.; Shao, Z.M. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene, 2009, 28, 3937-3948.
95. Xie, C.; Jiang, X.H.; Zhang, J.T.; Sun, T.T.; Dong, J.D.; Sanders, A.J.; Diao, R.Y.; Wang, Y.; Fok, K.L.; Tsang, L.L.; Yu, M.K.; Zhang, X.H.; Chungl Y.W.; Ye, L.; Zhao, M.Y.; Guo, J.H.; Xiao, Z.J.; Lan. H.Y.; Ng, C.F.; Lau, K.M.; Cai, Z.M.; Jiang, W.G.; Chan, H.C. CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer. Oncogene, 2013, 32, 2282-2289.
96. Hu, H.; Lim, S.; Liu, J.; Ni, B. MicroRNA-193b modulates proliferation, migration, and invasion of non-small cell lung cancer cells. Acta Biochim. Biophys. Sin. (Shanghai), 2012, 44, 424-430.
97. Mitra, A.K.; Chiang, C.Y.; Tiwari, P.; Tomar, S.; Watters, K.M.; Peter, M.E.; Lengyel. E. Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis. Oncogene, 2015, 34, 5923-5932.
98. Li, J.; Kong, F.; Wu, K.; Song, K.; He, J.; Sun, W. miR-193b directly targets STMN1 and uPA genes and suppresses tumor growth and metastasis in pancreatic cancer. Mol. Med. Rep., 2014, 10, 2613-2622.
99. Ge, L.; Zheng, B.; Li, M.; Niu, L.; Li, Z. MicroRNA-497 suppresses osteosarcoma tumor growth in vitro and in vivo. Oncol. Lett., 2016, 11, 2207-2212.
100. Derynck, R.; Zhang, Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 2003, 425, 577-584.
101. Santibanez, J.F.; Iglesias, M.; Frontelo, P.; Martinez, J.; Quintanilla, M. Involvement of the Ras/MAPK signaling pathway in the modulation of urokinase production and cellular invasiveness by transforming growth factor-beta(1) in transformed keratinocytes. Biochem. Biophys. Res. Commun., 2000, 273, 521-527.
102. Villar, V.; Kocić, J.; Santibanez, J.F. Spred2 inhibits TGF-beta1-induced urokinase type plasminogen activator expression, cell motility and epithelial mesenchymal transition. Int. J. Cancer, 2010, 127, 77-85.
103. Santibanez, J.F. JNK mediates TGF-beta1-induced epithelial mesenchymal transdifferentiation of mouse transformed keratinocytes. FEBS Lett., 2006, 580, 5385-5391.
104. Tobar, N.; Villar, V.; Santibanez, J.F. ROS-NFkappaB mediates TGF-beta1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion. Mol. Cell. Biochem., 2010, 340, 195-202.
105. Kocic, J.; Bugarski, D.; Santibanez, J.F. SMAD3 is essential for transforming growth factor-β1-induced urokinase type plasminogen activator expression and migration in transformed keratinocytes. Eur. J. Cancer, 2012, 48, 1550-1557.
106. Miralles, F.; Parra, M.; Caelles, C.; Nagamine, Y.; Felez. J.; Munoz-Canoves, P. UV irradiation induces the murine urokinase-type plasminogen activator gene via the c-Jun N-terminal kinase signaling pathway: Requirement of an AP1 enhancer element. Mol. Cell. Biol., 1998, 18, 4537-4547.
107. Shin, E.Y.; Ma, E.K.; Kim, C.K.; Kwak, S.J.; Kim, E.G. Src/ERK but not phospholipase D is involved in keratinocyte growth factorstimulated secretion of matrix metalloprotease-9 and urokinase-type plasminogen activator in SNU-16 human stomach cancer cell. J. Cancer Res. Clin. Oncol., 2002, 128, 596-602.
108. Lee, K.H.; Choi, E.Y.; Kim, M.K.; Hyun, M.S.; Jang, B.I.; Kim, T.N.; Kim, S.W.; Song, S.K.; Kim, J.H.; Kim, J.R. Regulation of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MEK/ERK activation in human stomach cancer cell lines. Exp. Mol. Med., 2006, 38, 27-35.
109. Lee, K.H.; Choi, E.Y.; Koh, S.A.; Kim, M.K.; Jang, B.I.; Kim, S.W.; Kim, J.R. IL-1β-stimulated urokinase plasminogen activator expression through NF-κB in gastric cancer after HGF treatment. Oncol. Rep., 2014, 31, 2123-2130.
110. Ghasemi, A.; Hashemy, S.I.; Aghaei, M.; Panjehpour, M. RhoA/ROCK pathway mediates leptin-induced uPA expression to promote cell invasion in ovarian cancer cells. Cell Signal., 2017, 32, 104-111.
111. He, X.; Zheng, Z.; Li, J.; Ben, Q.; Liu, J.; Zhang, J.; Ji, J.; Yu, B.; Chen, X.; Su, L.; Zhou, L.; Liu, B.; Yuan, Y. DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA. Carcinogenesis, 2012, 33, 555-562.
112. Min, H.J.; Lee, Y.; Zhao, X.F.; Park, Y.K.; Lee, M.K.; Lee, J.W.; Kim, S. TMPRSS4 upregulates uPA gene expression through JNK signaling activation to induce cancer cell invasion. Cell Signal., 2014, 26, 398-408.
113. Kleiner, S.; Faisal, A.; Nagamine, Y. Induction of uPA gene expression by the blockage of E-cadherin via Src-and Shc-dependent Erk signaling. FEBS J., 2007, 274, 227-240.
114. Eandi, J.A.; Yang, J.C.; Evans, C.P. Signal transduction-mediated regulation of urokinase gene expression in human prostate cancer. Biochem. Biophys. Res. Commun., 2001, 288, 521-527.
115. Shin, B.A.; Yoom H,G,; Kim, H.S.; Kim, M.H.; Hwang, Y.S.; Chay, K.O.; Lee, K.Y.; Ahn, B.W.; Jung, Y.D. P38 MAPK pathway is involved in the urokinase plasminogen activator expression in human gastric SNU-638 cells. Oncol. Rep., 2003, 10, 1467-1471.
116. Aguirre-Ghiso, J.A.; Alonso D.F.; Farias, E.F.; Gomez, D.E.; de Kier Joffe, E.B. Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur. J. Biochem., 1999, 263, 295-304.
117. Wang, S.; Boyd, D. Modulation of urokinase-type plasminogenactivator expression by the wild-type and mutated p53 tumorsuppressor gene. Int. J. Oncol., 1995, 7, 143-146.
118. Shetty, P.; Velusamy, T.; Bhandary, Y.P.; Shetty, R.S.; Liu, M.C.; Shetty S. Urokinase expression by tumor suppressor protein p53: A novel role in mRNA turnover. Am. J. Respir. Cell. Mol. Biol., 2008, 39, 364-372.
119. Au Yeung, C.L.; Tsang, T.Y.; Yau, P.L.; Kwok, T.T. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. Oncogene, 2011, 30, 2401-2410.
120. Niiya, M.; Niiya, K.; Shibakura, M.; Asaumi, N.; Yoshida, C.; Shinagawa, K; Teshima, T.;Ishimaru, F.; Ikeda, K.; Tanimotom M. Involvement of ERK1/2 and p38 MAP kinase in doxorubicininduced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells. Oncology, 2004, 67, 310-319.
121. Ertongur, S.; Lang, S.; Mack, B.; Wosikowski, K.; Muehlenweg, B.; Gires, O. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int. J. Cancer, 2004, 110, 815-824.
122. Goldstein, L.J. Experience in phase I trials and an upcoming phase II study with uPA inhibitors in metastatic breast cancer. Breast Care (Basel)., 2008, 3, 25-28.
123. Heinemann, V.; Ebert, M.P.; Laubender, R.P.; Bevan, P.; Mala, C.; Boeck, S. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with nonresectable, locally advanced pancreatic cancer. Br. J. Cancer, 2013, 108, 766-770.
124. Mishima, K.; Mazar.; A.P.; Gown, A.; Skelly, M.; Ji, X.D.; Wang, X.D.; Jones, T.R.; Cavenee, W.K.; Huang, H.J.S. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 8484-8489.
125. Gold, M.A.; Brady, W.E.; Lankes, H.A.; Rose, P.G.; Kelley, J.L.; De Geest. K.; Crispens, M.A.; Resnick, K.E.; Howell, S.B. A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study. Gynecol. Oncol., 2012, 125, 635-639.
126. Ghamande, S.A.; Silverman, M.H.; Huh, W.; Behbakht, K.; Ball. G.; Cuasay, L.; Wurtz, S.O.; Brunner, N.; Gold, M.A. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol. Oncol., 2008 , 111, 89-94.
127. Persson, M.; Skovgaard, D.; Brandt-Larsen, M.; Christensen, C.; Madsen, J.; Nielsen, C.H.; Thurison, T.; Klausen, T.L.; Holm, S.; Loft, A.; Berthelsen, A.K. First-in-human uPAR PET: Imaging of cancer aggressiveness. Theranostics, 2015, 5, 1303-1316
128. Ploug, M.; Ostergaard, S.; Gardsvoll, H.; Kovalski, K.; Holst-Hansen, C.; Holm, A.; Ossowski, L.; Dano, K. Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry, 2001, 40, 12157-12168.
129. Pillay, V.; Dass, C.R.; Choong, P.F. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol., 2007, 25, 33-39.
130. Pulukuri, S.M.; Gondi, C.S.; Lakka, S.S.; Jutla, A.; Estes. N.; Gujrati, M.; Rao, J.S. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J. Biol. Chem., 2005, 280, 36529-3640.
131. Kondraganti, S.; Gondi, C.S.; McCutcheon, I, Dinh. D.H.; Gujrati, M.; Rao, J.S.; Olivero, W.C. RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth. Int. J. Oncol., 2006, 28, 1353-1360.
132. Zhang, Y.; Kenny, H.A.; Swindell, E.P.; Mitra, A.K.; Hankins, P.L.; Ahn, R.W.; Gwin, K.; Mazar, A.P.; O'Halloran, T.V.; Lengyel. E. Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Mol. Cancer. Ther., 2013, 12, 2628-2639.
133. Cardote, T.A.; Ciulli, A. Cyclic and macrocyclic peptides as chemical tools to recognise protein surfaces and probe protein-protein interactions. ChemMedChem., 2016, 11, 787-794.
134. Jiang, L.; Svane, A.S.; Sorensen, H.P.; Jensen, J.K.; Hosseini, M.; Chen, Z.; Weydert, C.; Nielsen, J.T.; Christensen, A.; Yuan, C.; Jensen, K.J. The binding mechanism of a peptidic cyclic serine protease inhibitor. J. Mol. Biol., 2011, 412, 235-250.
135. Roodbeen, R.; Paaske, B.; Jiang, L.; Jensen, J.K.; Christensen, A.; Nielsen, J.T. Bicyclic peptide inhibitor of urokinase-type plasminogen activator: Mode of action. Chembiochem., 2013, 14, 2179-2188.
136. Hosseini, M.; Jiang, L.; Sorensen, H.P.; Jensen, J.K.; Christensen, A.; Fogh, S.; Yuan, C.; Andersen, L.M.; Huang, M.; Andreasen, P.A.; Jensen, K.J. Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs. Mol. Pharmacol., 2011, 80, 585-597.
137. Waldron, N.N.; Oh, S.; Vallera, D.A. Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma. Oral Oncol., 2012, 48, 1202-7.
138. Schappa, J.T.; Frantz, A.M.; Gorden, B.H.; Dickerson, E.B.; Vallera, D.A.; Modiano, J.F. Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors. Int. J. Cancer, 2013, 133, 1936-1944.
139. Borgatti, A.; Koopmeiners, J.S.; Sarver, A.L.; Winter, A.L.; Stuebner, K.; Todhunter, D.; Rizzardi, A.E.; Henricksen, J.C.; Schmechel, S.; Forster, C.L.; Kim. J.H.; Froelich. J.; Walz. J.; Henson, M.S; Breen, M; Lindblad-Toh, K.; Oh. F.; Pilbeam, K.; Modiano, J.F.; Vallera, D.A. Safe and effective sarcoma therapy through bispecific targeting of EGFR and uPAR. Mol. Cancer Ther., 2017, 16(5), 956-965.
140. Krstic, J.; Maslovaric, I.; Santibanez, J.F. Novel patents and cancer therapies for transforming growth factor-beta and urokinase type plasminogen activator: Potential use of their interplay in tumorigenesis. Rec. Pat. Anticancer Drug Discov., 2014, 9, 354-371.
141. Glaire, M.A.; El-Omar, E.M.; Wang, T.C.; Worthley, D.L. The mesenchyme in malignancy: A partner in the initiation, progression and dissemination of cancer. Pharmacol. Ther., 2012, 136, 131-141.